ClinicalTrials.gg
Not yet recruitingNCT06175468Updated Dec 19, 2023

Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease

A Phase 3 interventional study of Formosa 1-Breath Free (NRICM101) and Placebo control drug in Influenza Viral Infections and COVID-19, sponsored by China Medical University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by China Medical University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in COVID-19 with a site in Taiwan — 12 open to participants now, 13 under way, 7 of them phase 3. COVID-19 · Taiwan.

Planned enrollment
27th of 56
170 · median 137
Started
2023
with 9 others
Phase 3
11 of 78
6 open now
Primary completion
2024-04
later than 1 of 12 live
Registered
63rd of 78
by date

Among the 78 studies in COVID-19 with a site in Taiwan, this one is the 27th largest by planned enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2023, is one of 11 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 63rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 78 studies in COVID-19 with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in COVID-19 with a site in Taiwan, or all of them as a file.
02

Study summary

"Formosa 1-Breath Free (NRICM101) " has been widely known in Taiwan to treat COVID-19. However, there is no phase III pivotal clinical trial of "Formosa 1-Breath Free (NRICM101) " . In order to obtain scientific, standardized, and comparable clinical results, the study will be implemented to evaluate the efficacy of safety of "Formosa 1-Breath Free (NRICM101) ".

The objective of the study was used the product which be provided by Tian-I Pharmaceutical Co. Ltd. to evaluate the efficacy and safety of the subjects with the symptoms of COVID-19 or Influenza-like after taking "Formosa 1-Breath Free (NRICM101) ".

This study is a randomized, double-blind, parallel controlled clinical trial. The study consisted of 3 cycles: screening period, treatment period (5 days) and follow-up period. The treatment of this study is divided into two groups: The test drug is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day;The control drug is the placebo (dummy) 5g/bag, 3 times a day. The sample size in the study is at least 150 people who can be evaluated, and the dropout rate of the test is 10-15%. The estimated sample size is around 170 people. After signing the ICF, vital signs (sitting blood pressure, pulse rate, SpO2, respiratory rate and body temperature), physical examination, chest X-ray, and laboratory test will be checked in screening period. Only subjects with clinically acceptable and following the inclusion and exclusion criteria will eligible to enroll in this study. Compliance will be assured by administration of the study drug under the supervision of the investigator or his deputy. Subjects will be free to withdraw at any time without stating any reason. Data will be analyzed from those subjects who complete the entire study; however, the case report forms and the final study report should include reasons for withdrawals and any necessary treatment.

03

Conditions studied

  • Influenza Viral Infections
  • COVID-19

Keywords

  • Formosa 1-Breath Free (NRICM101)
  • COVID-19
  • Influenza
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who meet the criteria guideline in the "Seasonal Influenza Prevention and Control Manual" recommended by the Taiwan Centers for Disease Control, or are determined by the investigator to have mild symptoms of COVID-19, including fever, sore throat, cough, and fatigue.
  • Subjects who have had a fever (body temperature ≥37.5°C and ≤39°C) before their initial dose.
  • Throat pain intensity score >30 points during the screening period.
  • Cough severity score >3 points during the screening period.
  • Fatigue level score >30 points during the screening period.
  • Able to perform activities of daily living and aged 20 weeks or older.
  • Duration of illness ≤24 hours.
  • Obtained from the subject and signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Subject has used other medications for this condition (including cold medicine, antibiotics, antiviral drugs, and similar traditional Chinese medicines) within the 24 hours prior to screening, or is determined by the investigator to require the use of antibiotics or COVID-19 anti-virus drugs.
  • Subject has used or NSAIDs for an extended period within the four weeks prior to screening.
  • Subject has had poorly controlled chronic diseases in the past five years, including cardiovascular, respiratory, gastrointestinal, immune-related conditions, or mental health disorders (as determined by the investigator).
  • Subject has had chronic bronchitis, streptococcal pharyngitis, herpetic pharyngitis, or pneumonia within the past two years or at the time of screening (as determined by the investigator).
  • Subject is allergic to the drug or its components.
  • Women who are pregnant, breastfeeding, or planning to become pregnant.
  • Subject has participated in other drug clinical trials within the 90 days prior to screening.
  • The investigator evaluates the subject unsuitable for inclusion in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
170 participants (estimated)

Study arms

  • Placebo comparator
    Placebo control group

    take the placebo drug 5g/bag、three times a day, treatment for 5 days

    Drug: Placebo control drug

  • Active comparator
    Treatment group

    take the Formosa 1-Breath Free (NRICM101) 5g/bag、three times a day, treatment for 5 days

    Drug: Formosa 1-Breath Free (NRICM101)

Interventions

  • DrugFormosa 1-Breath Free (NRICM101)

    After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.

  • DrugPlacebo control drug

    After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.

06

What researchers measure

Primary outcomes

  1. Sore Throat Visual Analogue Scale (VAS)

    Assessing the improvement in sore throat in subjects with symptoms of COVID-19 or influenza-like symptoms. Using the Visual Analogue Scale (VAS) with a range of 0-100, the absolute value of the baseline change in pain intensity is calculated as the Sum of Pain Intensity Differences (SPID), serving as an indicator of the degree of therapeutic improvement.

    Time frame: Sore throat will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

Secondary outcomes

  1. Cough Cough Symptom Score (CSS)

    Evaluate the improvement in the severity of cough in subjects with symptoms of COVID-19 or influenza-like symptoms. Use the Cough Symptom Score (CSS) to calculate the baseline change as an indicator of the degree of therapeutic improvement.

    Time frame: Cough will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

  2. Fatigue Visual Analogue Scale (VAS)

    Assess the improvement in fatigue in subjects with symptoms of COVID-19 or influenza-like symptoms. Use the Visual Analogue Scale (VAS) with a range of 0-100 as an indicator to calculate the absolute value of baseline change as a measure of therapeutic improvement.

    Time frame: Fatigue will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

  3. Nasal Symptoms Total Nasal Symptom Score (TNSS)

    Assess the improvement in nasal symptoms in subjects with symptoms of COVID-19 or influenza-like symptoms. Use total nasal symptom score (TNSS) with a range of 0-100 as an indicator to calculate the absolute value of baseline change as a measure of therapeutic improvement.

    Time frame: Nasal symptoms will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days

  4. Fever Level

    Evaluate the improvement in fever in subjects with symptoms of COVID-19 or influenza-like symptoms. Calculate the time (in hours) from the first dose of medication to the first onset of temperature relief, as well as the time from complete relief to a normal value. Temperature relief is defined as a temperature below 37.5°C, and the time for final complete relief is the point in time after the last occurrence of fever when the temperature returns to normal. Additionally, calculate the baseline change in temperature for each measurement as an indicator of therapeutic improvement.

    Time frame: Fever measurements will be taken before the first dose, and one hour after each dose for 5 days

  5. Safety evaluation

    Evaluate the safety of subjects with symptoms of COVID-19 or influenza-like symptoms after administration of the medication to the end of study

    Time frame: Record the adverse event form the baseline to the end of study and follow up to 14 days

  6. Traditional Chinese Medicine (TCM) Syndrome Severity

    Evaluate the improvement in Traditional Chinese Medicine (TCM) syndrome severity in subjects with symptoms of COVID-19 or influenza-like symptoms. Assess the TCM syndrome efficacy using two TCM syndrome scoring scales for primary and secondary symptoms, respectively. Calculate the total scores for the primary symptom scale, the total scores for the secondary symptom scale, and the total syndrome scores (including both primary and secondary symptoms) as indicators of baseline change in absolute values.

    Time frame: The Traditional Chinese Medicine (TCM) syndrome will be assessed by the physician during the screening period and at the final follow-up visit up to 14 days.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Apr 2024, 4 months later.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 4 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 19, 2023
StartEst.
Dec 15, 2023
Primary completionEst.
Apr 2024
CompletionEst.
Aug 2024
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06175468
Collaborators
Tian-I Pharmaceutical,. Co. Ltd., China Medical University, China, Qualitix Clinical Research Co., Ltd.
Responsible party
Sponsor
First posted
Dec 19, 2023
Start date
Dec 15, 2023 (estimated)
Primary completion
Apr 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Dec 19, 2023

Study contacts

Chia-Ing Li, PhD
Contact
006446@tool.caaumed.org.tw
+ 886-4-22052121 ext. 14701
Chia-Ing Li, PhD
study chair · Associate Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion